Cargando…
Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authori...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947939/ https://www.ncbi.nlm.nih.gov/pubmed/36823160 http://dx.doi.org/10.1038/s41541-023-00622-0 |
_version_ | 1784892670436442112 |
---|---|
author | Jacob-Dolan, Catherine Yu, Jingyou McMahan, Katherine Giffin, Victoria Chandrashekar, Abishek Martinot, Amanda J. Anioke, Tochi Powers, Olivia C. Hall, Kevin Hope, David Miller, Jessica Hachmann, Nichole P. Chung, Benjamin Gardner, Sarah Sellers, Daniel Barrett, Julia Lewis, Mark G. Andersen, Hanne Kleanthous, Harry Seo, Ki-Woen Lee, Su Jeen Park, Yong Wook Kim, Hun Barouch, Dan H. |
author_facet | Jacob-Dolan, Catherine Yu, Jingyou McMahan, Katherine Giffin, Victoria Chandrashekar, Abishek Martinot, Amanda J. Anioke, Tochi Powers, Olivia C. Hall, Kevin Hope, David Miller, Jessica Hachmann, Nichole P. Chung, Benjamin Gardner, Sarah Sellers, Daniel Barrett, Julia Lewis, Mark G. Andersen, Hanne Kleanthous, Harry Seo, Ki-Woen Lee, Su Jeen Park, Yong Wook Kim, Hun Barouch, Dan H. |
author_sort | Jacob-Dolan, Catherine |
collection | PubMed |
description | Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authorized for marketing in South Korea under the trade name SKYCovione(TM). The antigen in GBP510/AS03 is a two-part recombinant nanoparticle, which displays 60 receptor binding domain (RBD) proteins of SARS-CoV-2 Spike on its surface. In this study we show that GBP510/AS03 induced robust immune responses in rhesus macaques and protected against a high-dose SARS-CoV-2 Delta challenge. We vaccinated macaques with two or three doses of GBP510/AS03 matched to the ancestral Wuhan strain of SARS-CoV-2 or with two doses of GBP510/AS03 matched to the ancestral strain and one dose matched to the Beta strain. Following the challenge with Delta, the vaccinated macaques rapidly controlled the virus in bronchoalveolar lavage and nasal swabs. Binding and neutralizing antibody responses prior to challenge correlated with protection against viral replication postchallenge. These data are consistent with data with this vaccine from the phase 3 clinical trial. |
format | Online Article Text |
id | pubmed-9947939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99479392023-02-23 Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques Jacob-Dolan, Catherine Yu, Jingyou McMahan, Katherine Giffin, Victoria Chandrashekar, Abishek Martinot, Amanda J. Anioke, Tochi Powers, Olivia C. Hall, Kevin Hope, David Miller, Jessica Hachmann, Nichole P. Chung, Benjamin Gardner, Sarah Sellers, Daniel Barrett, Julia Lewis, Mark G. Andersen, Hanne Kleanthous, Harry Seo, Ki-Woen Lee, Su Jeen Park, Yong Wook Kim, Hun Barouch, Dan H. NPJ Vaccines Article Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authorized for marketing in South Korea under the trade name SKYCovione(TM). The antigen in GBP510/AS03 is a two-part recombinant nanoparticle, which displays 60 receptor binding domain (RBD) proteins of SARS-CoV-2 Spike on its surface. In this study we show that GBP510/AS03 induced robust immune responses in rhesus macaques and protected against a high-dose SARS-CoV-2 Delta challenge. We vaccinated macaques with two or three doses of GBP510/AS03 matched to the ancestral Wuhan strain of SARS-CoV-2 or with two doses of GBP510/AS03 matched to the ancestral strain and one dose matched to the Beta strain. Following the challenge with Delta, the vaccinated macaques rapidly controlled the virus in bronchoalveolar lavage and nasal swabs. Binding and neutralizing antibody responses prior to challenge correlated with protection against viral replication postchallenge. These data are consistent with data with this vaccine from the phase 3 clinical trial. Nature Publishing Group UK 2023-02-23 /pmc/articles/PMC9947939/ /pubmed/36823160 http://dx.doi.org/10.1038/s41541-023-00622-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jacob-Dolan, Catherine Yu, Jingyou McMahan, Katherine Giffin, Victoria Chandrashekar, Abishek Martinot, Amanda J. Anioke, Tochi Powers, Olivia C. Hall, Kevin Hope, David Miller, Jessica Hachmann, Nichole P. Chung, Benjamin Gardner, Sarah Sellers, Daniel Barrett, Julia Lewis, Mark G. Andersen, Hanne Kleanthous, Harry Seo, Ki-Woen Lee, Su Jeen Park, Yong Wook Kim, Hun Barouch, Dan H. Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title | Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title_full | Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title_fullStr | Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title_full_unstemmed | Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title_short | Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques |
title_sort | immunogenicity and protective efficacy of gbp510/as03 vaccine against sars-cov-2 delta challenge in rhesus macaques |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947939/ https://www.ncbi.nlm.nih.gov/pubmed/36823160 http://dx.doi.org/10.1038/s41541-023-00622-0 |
work_keys_str_mv | AT jacobdolancatherine immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT yujingyou immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT mcmahankatherine immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT giffinvictoria immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT chandrashekarabishek immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT martinotamandaj immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT anioketochi immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT powersoliviac immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT hallkevin immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT hopedavid immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT millerjessica immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT hachmannnicholep immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT chungbenjamin immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT gardnersarah immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT sellersdaniel immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT barrettjulia immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT lewismarkg immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT andersenhanne immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT kleanthousharry immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT seokiwoen immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT leesujeen immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT parkyongwook immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT kimhun immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques AT barouchdanh immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques |